News
FDA UpdatesLaw and AdvocacyTechnology TrendsViewpointsAll News
Media
In-Depth InsightsPharmacist ViewScript-EdExpert InterviewsPharmacy PerspectivesPodcasts
Conferences
Conference CoverageConference Listing
Resources
Disease Awareness White Board VideoAmerican Pharmacists MonthSponsored ResourcesCME/CEPartners
More
Publications
Drug Topics JournalTotal Pharmacy JournalSubmission of ArticlesSupplements And Featured Publications
Events
Virtual EventsTotal Pharmacy Solutions Summit
Business
Business StrategiesPatient ServicesPharmacy InventoryLaw and RegulationsTechnology and DataAll Business News
Practice Type
Independent PharmacyChain PharmacySpecialty PharmacyHealth System PharmacyPharmacy Technicians
Total Pharmacy

Subscribe

  • News
  • Media
  • Conferences
  • Resources
  • Publications
  • Events
  • Business
  • Practice Type
  • Subscribe
  • Total Pharmacy
  • Allergy
  • Autoimmune Diseases
  • Biosimilars
  • COVID-19
  • Cannabidiol (CBD)
  • Cardiology
  • Compounding
  • Continuous Glucose Monitoring
  • Dermatology
  • Diabetes
  • Digestive Health
  • Endocrinology
  • Eye Health
  • Generics
  • HIV
  • Headache and Migraine
  • Immunization
  • Infectious Disease
  • Influenza
  • Insulin Management
  • Medical Devices
  • Mental and Behavioral Health
  • Neurology
  • OTC
  • Obesity Management
  • Oncology
  • Pain Management
    • Nonopioid Pain Management
  • Pediatrics
  • Pneumococcal
  • Public Health
  • Rare Diseases
  • Respiratory
  • Rheumatology
  • Shingles
  • Specialty Pharmacy
  • Substance Use Disorder
  • Technology and Data
  • Veterinary Pharmacy
  • Women's Health
Spotlight -
NCPA Annual Convention|
FDA Updates|
Total Pharmacy
Advertisement

Katelyn Yamartino, PharmD

Advertisement

Articles by Katelyn Yamartino, PharmD

heart disease

Vericiguat (Verquvo) for Heart Failure With Reduced Ejection Fraction

ByKatelyn Yamartino, PharmD,Kevin W. Chamberlin, PharmD
March 16th 2021

A new drug review for vericiguat, indicated for heart failure, reports efficacy and safety data.

Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults

ByKatelyn Yamartino, PharmD,Kevin W. Chamberlin, PharmD
November 11th 2020

An overview of the use of satralizumab-mwge (Enspryng; Genentech) in neuromyelitis optica spectrum disorder (NMOSD).

Advertisement

Latest Updated Articles

  • Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults
    Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults

    Published: November 11th 2020 | Updated:



Advertisement
Advertisement

Trending on Drug Topics

1

As Pharmacists Enter More Clinical Roles, So Do Pharmacy Technicians | ASHP Midyear 2025

2

Pharmacists Help Patients Manage Insulin Pumps for Type 2 Diabetes | ASHP Midyear 2025

3

Pharmacists Now Authorized to Independently Prescribe Buprenorphine

4

Pharmacists Remain Health Care Focal Point as Vaccine Recommendations Change

5

Bridging Barriers in Health Care Delivery to Push Pharmacy’s Path Forward

  • About
  • Advertise
  • Editorial
  • Editorial Board
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • AdvanCE
  • Total Pharmacy
Drug Topics
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us